President Donald Trump’s tariffs may cause an increase in empty pharmaceutical shelves. According to an AP report, Trump’s plan to impose steep import taxes on pharmaceuticals — some as high as 200% — is drawing sharp warnings from industry experts who fear it could push up drug prices in the United States and trigger shortages.
“A tariff would hurt consumers most of all, as they would feel the inflationary effect … directly when paying for prescriptions at the pharmacy and indirectly through higher insurance premiums,” wrote Diederik Stadig of ING, adding that low-income households and the elderly would be most exposed.
READ: Who lost India? Trump’s tariff approach puts a generation of U.S.-India progress at risk (August 19, 2025)
“Shock and awe is how this industry is going from zero (tariffs) to the potential of 200%,” Maytee Pereira of PwC told AP.
“The only way to truly protect yourself from the tariffs would be to build the supply chain end to end in the United States,” Pereira said.
Trump’s administration pushed forward with imposing steep tariffs on imported pharmaceuticals, invoking national security concerns under Section 232 of the Trade Expansion Act. These tariffs, reaching up to 200% on select drug imports, aim to reduce U.S. dependency on foreign pharmaceutical manufacturers and promote domestic production. The move is part of Trump’s broader trade strategy to strengthen American industry and address vulnerabilities in supply chains, particularly highlighted by disruptions during the COVID-19 pandemic.
Though Trump has suggested a one-year delay to give drugmakers time to stockpile or shift production to the U.S., analysts told AP the impact could still hit by 2027 or 2028 as inventories run down.
While the administration argues that these tariffs are vital for national security and economic stability, critics warn they risk raising drug prices and limiting access to essential medicines for millions of Americans. Major pharmaceutical companies like Eli Lilly and Johnson & Johnson have responded by increasing investments in domestic manufacturing to offset potential impacts.
However, the tariffs have faced significant legal challenges with courts ruling that the administration overstepped its authority by imposing such tariffs without explicit congressional approval. The U.S. Court of Appeals for the Federal Circuit struck down parts of the tariffs, arguing that such sweeping economic policies require clear legislative backing. This ruling was temporarily stayed, allowing tariffs to remain in place pending appeals.
The case is now set to be reviewed by the U.S. Supreme Court with its decision expected to have far-reaching implications for executive power and trade policy in the United States. The pharmaceutical tariffs controversy continues to fuel a heated debate over the balance between national security, economic interests, and the potential costs borne by consumers in the evolving landscape of global trade.
Drugmakers have increasingly offshored production to countries such as China, India, Ireland and Switzerland, leaving the U.S. with a nearly $150 billion trade deficit in pharmaceuticals last year. Analysts noted that 97% of antibiotics, 92% of antivirals and 83% of top generic drugs rely on at least one active ingredient manufactured abroad.
While the intent to reduce reliance on foreign drug manufacturing aims to strengthen domestic production and supply chain resilience, the immediate consequences risk disrupting access to affordable medicines. Higher tariffs could lead to increased drug prices, affecting millions, especially vulnerable groups like low-income families and the elderly.
Trump also seems to be changing his stance on vaccines. In a recent Truth Social post, Trump backed Health and Human Services Secretary Robert F. Kennedy Jr. amid debates over vaccine safety and efficacy, marking a significant shift from his prior endorsements.
Though it doesn’t seem like Trump has explicitly embraced Kennedy’s long-standing anti-vaccine rhetoric, his alignment with Kennedy’s aggressive reshaping of health institutions has fueled concern among public health experts. This evolution in Trump’s stance suggests both political recalibration and growing internal tension within the administration over vaccine policy and scientific oversight.
Trump has demanded that Pfizer and other pharmaceutical companies release full data on their COVID-19 vaccines, questioning the success of Operation Warp Speed, which he once praised as a triumph.
Legal challenges and ongoing court battles reflect the complexity of enforcing such sweeping trade measures without clear congressional authorization, underscoring broader debates about executive power and trade policy. The controversy also sheds light on the deep global integration of pharmaceutical supply chains and the challenges the U.S. faces in reshoring critical industries.